The dose of orally administered 9-deazainosine calculated to suppress 50% of Leishmania donovani amastigotes in hamster livers was 19 mg/kg (body weight) per day; 96 to 99% of Leishmania organisms were eliminated from the liver and spleen of squirrel monkeys by 50 mg/kg per day. Because these activities were greater than that of the experimental clinical agent allopurinol and comparable to that of the classical agent parenteral pentavalent antimony, 9-deazainosine should be considered for clinical development for visceral leishmaniasis.
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Visceral leishmaniasis results from parasitization of the macrophages of the liver and other components of the visceral monocyte-phagocyte system by Leishmania donovani. Although parenteral administration of pentavalent antimony (Sb) complexed to carbohydrates in the form of sodium stibogluconate (Pentostam) or meglumine antimonate (Glucantime) is generally effective, the desirability of an orally administrable antileishmanial agent has led to intense interest in the antileishmanial potential of purine analogs, such as allopurinol and allopurinol ribonucleoside, which are apparently specifically metabolized by the parasites (reviewed in reference 8).
Recent in vitro work by Marr and co-workers indicated that the inosine analog 9-deazainosine might be more active but not markedly more toxic than allopurinol ribonucleoside and, presumably, allopurinol itself against L. donovani (9). These observations and the need to test antileishmanial purines against L. donovani in vivo led to the determination of the activity of such compounds against L. donovani in hamsters and squirrel monkeys.
The activity of antileishmanial drugs against L. donovaniinfected hamsters was determined as previously described (4) . In brief, 60-to 80-g male hamsters (Mesocricetus auratus) were infected via intracardiac injection with approximately 107 L. donovani amastigotes (Khartoum strain, WR 378). On days 3 to 6 after infection, groups of animals (six to eight hamsters each) were given hydroxyethylcellulose-Tween 80 (vehicle controls) or meglumine antimonate (positive controls) via the intramuscular route or purine analogs dissolved in vehicle via the oral route. The hamsters were killed 1 day after the last administration of drug, i.e., 1 week after infection, and the number of parasites per liver cell nucleus was determined from Giemsa-stained impression smears. This number was multiplied by the approximate number of liver nuclei per milligram of liver (200,000; reference 4) and by the weight of the liver to calculate the total number of parasites per liver.
The activity of meglumine antimonate and 9-deazainosine against L. donovani-infected squirrel monkeys (Saimiri sciureus) was determined as recently described (7 Although the in vivo and in vitro models use different organisms, the rank order of activity of these agents was the same in the two models, and for some of the drugs the G value ratios were comparable to the ratios of the in vitro ED50s. The comparable data from in vitro and in vivo tests in these two models suggest that the activity of novel purines might be appropriately determined by the use of these two models with a formycin and with allopurinol as strongly active and weakly active control compounds. 9-Deazainosine was the only purine of which there was a dosage that eliminated >95% of parasites (i.e., that was essentially curative) and that did not also result in >>10% mean weight loss, which we arbitrarily chose as an indication of drug toxicity. 9-Deazainosine therefore underwent secondary testing against L. donovani in squirrel monkeys. Less than 2% of liver and splenic parasites survived treatment with 104 mg of meglumine antimonate per kg per day, and 2 to 6% of parasites survived 52 mg of meglumine antimonate per kg per day (Table 2 ). Less than 1% of liver parasites and about 4% of splenic parasites survived treatment with both the high dose (200 mg/kg per day) and the low dose (50 mg/kg per day) of 9-deazainosine. These data suggest that the activity of 50 mg of 9-deazainosine per kg per day is equivalent to that of 52 to 104 mg of meglumine antimonate per kg per day. The only abnormalities observed at necropsy were fatty livers, which were noted in all three monkeys given 200 mg of 9-deazainosine per kg per day and in one of three vehicle control animals. The presence of fatty livers in the monkeys given high-dose 9-deazainosine was verified by light microscopy. There was no histopathologic sign of toxicity in the kidneys, heart, brain, or lungs in this group.
Marr and co-workers found that 9-deazainosine had the most favorable ratio of leishmaniacidal dose-cell toxic dose in vitro (9) . Here, 9-deazainosine had the most favorable therapeutic index in L. donovani-infected hamsters. 9-Deazainosine was at least as active as meglumine antimonate in L. donovani-infected monkeys. In contrast to the virtual elimination of hepatosplenic parasites by 50 mg of 9-deazainosine per kg per day for 7 days, allopurinol ribonucleoside at a dosage of 400 mg/kg per day for 10 days was not significantly active in Aotus trivirgatus (W.L.H., unpublished data). We know of no other purine analogs that have been tested in L. donovani-infected nonhuman primates. The appearance of fatty livers without abnormalities in other examined tissues in all monkeys given high-dose 9- deazainosine suggests that the liver is the target organ for 9-deazainosine toxicity.
The demonstration that 9-deazainosine virtually eliminates hepatic parasites in L. donovani-infected hamsters and at 50 mg/kg per day for 7 days also virtually eliminates hepatosplenic Leishmania organisms in L. donovani-infected squirrel monkeys suggests that consideration be given to its development as an oral treatment for human visceral leishmaniasis.
